ONO-1110
ONO-1110 is an endocannabinoid synthesis regulator and indirect cannabinoid receptor modulator which is under development for the treatment of fibromyalgia, generalized anxiety disorder, interstitial cystitis, major depressive disorder…
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
ONO-1110 is an endocannabinoid synthesis regulator and indirect cannabinoid receptor modulator which is under development for the treatment of fibromyalgia, generalized anxiety disorder, interstitial cystitis, major depressive disorder, postherpetic neuralgia, and social phobia. It is taken orally. ONO-1110 is under development by Ono Pharmaceutical in Japan.
As of March 2025, the drug is in phase 2 clinical trials for all indications. Its chemical structure does not yet appear to have been disclosed.
See also
List of investigational antidepressants List of investigational fibromyalgia drugs List of investigational generalized anxiety disorder drugs List of investigational social anxiety disorder drugs
External links
Development Pipeline - Ono Pharmaceutical
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372024936 under CC BY-SA 4.0; modifications have been made.